Fermenta Biotech Limited (FERMENTA) fundamentals
Fermenta Biotech Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as FERMENTA (ISIN INE225B01021). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Fermenta Biotech Limited does
Fermenta Biotech Limited is an India-based company that is engaged in the manufacturing of vitamin D, active pharmaceutical ingredients (APIs), enzymes and providing environmental solutions services. It is also engaged in renting and selling properties. Its segments include Chemicals/Bulk Drug and Property. The Chemicals/Bulk Drug segment is engaged in the manufacturing and selling of chemicals, primarily bulk drugs and enzymes. The Property segment is involved in renting and sale of properties. It has a diverse range of products and services that cater to various industries, such as pharmaceuticals, dietary and nutritional supplements, food and beverage fortification, animal feed, veterinary and others. It provides proprietary specialized technologies through its enzyme portfolio across the biopharmaceutical product life cycle. It also offers a range of nutritional ingredients, such as fish oil-derived cholesterol for aquaculture nutrition, and vitamin AD2 premix, among others.
Valuation and market data
| Last close | ₹475.00 |
|---|---|
| Market capitalisation | ₹1,351 crore |
| Enterprise value | ₹1,375 crore |
| P/E (TTM) | 19.23 |
| Price to book | 3.37 |
| Price to sales (TTM) | 1.46 |
| Book value per share | ₹140.84 |
| Dividend yield | 78.95% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹474 crore | ₹89 crore | ₹64 crore | 22.13 |
| Mar 2025 | ₹442 crore | ₹74 crore | ₹68 crore | 23.18 |
| Mar 2024 | ₹315 crore | ₹-5 crore | ₹-19 crore | -6.49 |
| Mar 2023 | ₹337 crore | ₹-58 crore | ₹-57 crore | -19.75 |
| Mar 2022 | ₹395 crore | ₹43 crore | ₹30 crore | 10.48 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jul 2026:
| Promoters | 64.1% |
|---|---|
| Foreign institutions (FII) | 0.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 35.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.